Phosphoprotein Phosphatase Type 4: A Novel Target for Therapeutic Cancer Treatment
Friday, November 7, 2014
Plaza Foyer (Sheraton)
Overexpression of phosphoprotein phosphatase type four (PP4) may contribute to cancer survival and metastasis. The development of a PP4 inhibitor will not only yield a valuable research tool for studying the pathology of diseases associated with PP4, but it could also result in the development of a new antitumor therapy.